...In an unexpected friendly tilt, the acquisitive Frankfurt-based Qiagen has offered $341m ($3.55 a share) in cash for Cellestis, a global purveyor of Quantiferon tuberculosis testing kits. The offer -- which might be bolstered by a special franked dividend -- is a 24 per cent premium on Friday's closing price.
....Alas, Criterion had Cellestis as an avoid at $2.75 on February 15, citing the generous multiples on which the stock was trading. The stock is now a hold.
